|
|
|
| Curative Efficacy of Insulin Sensitizer in Treatment of Type 2 Diabetes Intensive Treatment after Long-term Remission and its Effects on Urine Microalbumin |
| CHEN Hongxia, et al |
| Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing 100026,China |
|
|
|
|
Abstract Objective: To study curative efficacy of insulin sensitizer in treatment of type 2 diabetes intensive treatment after long - term remission and its effects on urine microalbumin. Methods: 80 patients of type 2 diabetes mellitus who received therapy from April 2015 to April 2016 were selected as research objects. According to random number table method,those patients were divided into the observation group(n=40) and the control group(n=40). The control group was treated with secondary double-arc treatment,while the observation group was treated with Insulin sensitizer treatment.Then blood sugar,insulin,C peptide,HDL-C, LDL-C, Homa-IR and UAE level were compared. Results: After treatment,the level of FBG and PBG in observation group was less than the control group after 1 month and 2 months(P<0.05). There was no significant difference in HbA1c levels between the two groups after 1 and 2 months of treatment(P>0.05). Two groups of FINS levels in the treatment of 1, 2 months after the decline. There were no significant differences in FINS, PINS, FC-P and PC-P between the two groups after 1 and 2 months (P> 0.05). HDL-C indicator in Observation group was higher than the control group[(1.51±0.55) mmol/L vs(1.27±0.46)mmol/L](P<0.05). LDL-C indicator in Observation group was less than the control group[(2.92±0.71) mmol/L vs(3.36±0.79)mmol/L](P<0.05). UAE level in Observation group was less than the control group [(98.27±56.23) C/mg.(24h)-1vs(143.22±51.37) C/mg。(24h)-1](P<0.05). Conclusion: Insulin sensitizer treatment of type 2 diabetes can effectively reduce the level of blood glucose and FINS, so that the sensitivity of peripheral tissue in the insulin to improve and reduce the level of urinary albumin in patients with significant efficacy, worthy of promotion.
|
|
|
|
|
|
[1] 毛焕东.二甲双胍联合吡格列酮对2型糖尿病患者免疫状态的影响[J].中国老年学杂志,2012,35(2):407~408.
[2] 仇海燕,谢云,李露荃,等.2型糖尿病患者晨尿微量白蛋白/肌酐与24h尿微量白蛋白相关性分析[J].天津医药,2012,40(3):209~211.
[3] 屠印芳,于浩泳,李连喜,等.2型糖尿病患者血清镁离子水平与24h尿微量白蛋白的关系研究[J].中国全科医学,2012,15(7):751~754.
[4] Colca JR. The TZD insulin sensitizer Clue provides a new route into diabetes drug discovery[J]. Expert Opin Drug Discov, 2015, 10(12): 1259~1270.
[5] 黄宇清,刘蓉.胰岛素增敏剂对2型糖尿病患者一相分泌的影响[J].中国老年学杂志,2012,41(15):3357~3359.
[6] 王菁楠,顾明君,赵泽飞,等.西格列汀对2型糖尿病肾损害患者尿微量白蛋白的影响[J].中国新药与临床杂志,2013,32(4):289~292.
[7] Wang J, Zou T, Yang HX, et al. Insulin receptor binding motif tagged with IgG4 Fc (Yiminsu) works as an insulin sensitizer to activate Akt signaling in hepatocytes[J]. Genet Mol Res, 2015, 14(3): 8819~8828.
[8] 王娇,张如意,宋青青,等.中老年糖尿病高危人群尿微量白蛋白患病率及危险因素分析[J].实用医学杂志,2013,29(12):2026~2028.
[9] Yang X, Xu Z, Zhang C, et al. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells[J]. Biochim Biophys Acta, 2016, 5(16): 5~30243.
[10] Tseng HL, Yang SC, Yang SH, et al. Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice[J]. PLoS One, 2015, 10(3): e0120380. |
|
|
|
2018, Vol. 24 
